Compare
American Shared Hospital Services vs Exagen Inc. vs Personalis, Inc. vs BioNexus Gene Lab Corp
| Latest fiscal year | American Shared Hospital Services AMS | Exagen Inc. XGN | Personalis, Inc. PSNL | BioNexus Gene Lab Corp BGLC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $28.08M | $66.58M | $69.65M | $7.42M |
| Revenue growth (YoY) | -0.9% | +19.7% | -17.7% | -21.9% |
| Gross margin | 18.0% | 58.3% | 22.7% (computed) | 14.6% |
| Operating margin | -12.8% | -21.1% | -126.4% | -39.9% |
| Net margin | -5.5% | -30.0% | -116.7% | -40.2% |
| Net income | -$1.55M | -$19.95M | -$81.27M | -$2.98M |
| EPS (Diluted) | -$0.23 | -$0.93 | -$0.91 | n/a |
| Operating cash flow | $3.10M | -$13.62M | -$74.95M | -$1.84M |
| Free cash flow | -$4.54M | -$14.27M | -$79.45M | -$1.88M |
| Cash & equivalents | $3.46M | $32.22M | $124.25M | $2.49M |
| Total assets | $55.48M | $58.02M | $334.16M | $9.25M |
| Total liabilities | $27.79M | $40.57M | $72.98M | $637.9K |
| Shareholders' equity | $27.69M | $17.45M | $261.19M | $8.61M |
| Return on year-end equity | -5.6% | -114.3% | -31.1% | -34.6% |
| Shares outstanding | 6.58M | 22.91M | 102.48M | 2.42M |
Revenue, most recent five fiscal years
| Fiscal year | American Shared Hospital Services | Exagen Inc. | Personalis, Inc. | BioNexus Gene Lab Corp |
|---|---|---|---|---|
| Latest | $28.08M Ended 2025-12-31 | $66.58M Ended 2025-12-31 | $69.65M Ended 2025-12-31 | $7.42M Ended 2025-12-31 |
| 1 year earlier | $28.34M Ended 2024-12-31 | $55.64M Ended 2024-12-31 | $84.61M Ended 2024-12-31 | $9.51M Ended 2024-12-31 |
| 2 years earlier | $21.32M Ended 2023-12-31 | $52.55M Ended 2023-12-31 | $73.48M Ended 2023-12-31 | $9.77M Ended 2023-12-31 |
| 3 years earlier | $19.75M Ended 2022-12-31 | $45.56M Ended 2022-12-31 | $65.05M Ended 2022-12-31 | $10.93M Ended 2022-12-31 |
| 4 years earlier | $17.63M Ended 2021-12-31 | $48.30M Ended 2021-12-31 | $85.49M Ended 2021-12-31 | $13.36M Ended 2021-12-31 |